|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fiteni F, Anota A, Westeel V and Bonnetain
F: Methodology of health-related quality of life analysis in phase
III advanced non-small-cell lung cancer clinical trials: A critical
review. BMC Cancer. 16:1222016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ettinger DS, Akerley W, Bepler G, Blum MG,
Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, et
al: Non-small cell lung cancer. J Natl Compr Canc Netw. 8:740–801.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zarogoulidis K, Zarogoulidis P, Darwiche
K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N,
Kougioumtzi I, Karapantzos I, Huang H and Spyratos D: Treatment of
non-small cell lung cancer (NSCLC). J Thorac Dis. 5(Suppl 4):
S389–S396. 2013.
|
|
5
|
Schabath MB, Nguyen A, Wilson P, Sommerer
KR, Thompson ZJ and Chiappori AA: Temporal trends from 1986 to 2008
in overall survival of small cell lung cancer patients. Lung
Cancer. 86:14–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li Z, Song Y, Liu L, Hou N, An X, Zhan D,
Li Y, Zhou L, Li P, Yu L, et al: miR-199a impairs autophagy and
induces cardiac hypertrophy through mTOR activation. Cell Death
Differ. 24:1205–1213. 2017. View Article : Google Scholar :
|
|
7
|
Mao M, Wu Z and Chen J: MicroRNA-187-5p
suppresses cancer cell progression in non-small cell lung cancer
(NSCLC) through down-regulation of CYP1B1. Biochem Biophys Res
Commun. 478:649–655. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zang H, Wang W and Fan S: The role of
microRNAs in resistance to targeted treatments of non-small cell
lung cancer. Cancer Chemother Pharmacol. 79:227–231. 2017.
View Article : Google Scholar
|
|
11
|
Aigner A: MicroRNAs (miRNAs) in cancer
invasion and metastasis: Therapeutic approaches based on
metastasis-related miRNAs. J Mol Med (Berl). 89:445–457. 2011.
View Article : Google Scholar
|
|
12
|
Rottiers V and Näär AM: MicroRNAs in
metabolism and metabolic disorders. Nat Rev Mol Cell Biol.
13:239–250. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cho WC: MicroRNAs: Potential biomarkers
for cancer diagnosis, prognosis and targets for therapy. Int J
Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar
|
|
14
|
Bienertova-Vasku J, Sana J and Slaby O:
The role of microRNAs in mitochondria in cancer. Cancer Lett.
336:1–7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bouyssou JM, Manier S, Huynh D, Issa S,
Roccaro AM and Ghobrial IM: Regulation of microRNAs in cancer
metastasis. Biochim Biophys Acta. 1845:255–265. 2014.PubMed/NCBI
|
|
16
|
Lang Y, Xu S, Ma J, Wu J, Jin S, Cao S and
Yu Y: MicroRNA-429 induces tumorigenesis of human non-small cell
lung cancer cells and targets multiple tumor suppressor genes.
Biochem Biophys Res Commun. 450:154–159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiao W, Zhong Y, Wu L, Yang D, Ye S and
Zhang M: Prognostic value of microRNAs in lung cancer: A systematic
review and meta-analysis. Mol Clin Oncol. 10:67–77. 2019.PubMed/NCBI
|
|
18
|
Zhan B, Lu D, Luo P and Wang B: Prognostic
value of expression of MicroRNAs in non-small cell lung cancer: A
systematic review and meta-analysis. Clin Lab. 62:2203–2211. 2016.
View Article : Google Scholar
|
|
19
|
Feng M, Zhao J, Wang L and Liu J:
Upregulated expression of serum exosomal microRNAs as diagnostic
biomarkers of lung adenocarcinoma. Ann Clin Lab Sci. 48:712–718.
2018.
|
|
20
|
Xia H, Li Y and Lv X: MicroRNA-107
inhibits tumor growth and metastasis by targeting the BDNF-mediated
PI3K/AKT pathway in human non-small lung cancer. Int J Oncol.
49:1325–1333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lou X, Qi X, Zhang Y, Long H and Yang J:
Decreased expression of microRNA-625 is associated with tumor
metastasis and poor prognosis in patients with colorectal cancer. J
Surg Oncol. 108:230–235. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou WB, Zhong CN, Luo XP, Zhang YY, Zhang
GY, Zhou DX and Liu LP: miR-625 suppresses cell proliferation and
migration by targeting HMGA1 in breast cancer. Biochem Biophys Res
Commun. 470:838–844. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Y, Tao C, Dai L, Cui C, Chen C, Wu H,
Wei Q and Zhou X: MicroRNA-625 inhibits cell invasion and
epithelial-mesen-chymal transition by targeting SOX4 in laryngeal
squamous cell carcinoma. Biosci Rep. 39:2019.
|
|
24
|
Wang M, Li C, Nie H, Lv X, Qu Y, Yu B, Su
L, Li J, Chen X, Ju J, et al: Down-regulated miR-625 suppresses
invasion and metastasis of gastric cancer by targeting ILK. FEBS
Lett. 586:2382–2388. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Van Schil PE, Rami-Porta R and Asamura H:
The 8th TNM edition for lung cancer: A critical analysis. Ann
Transl Med. 6:872018. View Article : Google Scholar :
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
27
|
Zhang B, Li N and Zhang H: Knockdown of
homeobox B5 (HOXB5) inhibits cell proliferation, migration, and
invasion in non-small cell lung cancer cells through inactivation
of the Wnt/β-catenin pathway. Oncol Res. 26:37–44. 2018. View Article : Google Scholar
|
|
28
|
Cheng X, Xu X, Chen D, Zhao F and Wang W:
Therapeutic potential of targeting the Wnt/β-catenin signaling
pathway in colorectal cancer. Biomed Pharmacother. 110:473–481.
2019. View Article : Google Scholar
|
|
29
|
Khalaf AM, Fuentes D, Morshid AI, Burke
MR, Kaseb AO, Hassan M, Hazle JD and Elsayes KM: Role of
Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis,
and clinical significance. J Hepatocell Carcinoma. 5:61–73. 2018.
View Article : Google Scholar :
|
|
30
|
Liu Z, Jiang L, Zhang G, Li S and Jiang X:
miR-24 promotes migration and invasion of non-small cell lung
cancer by targeting ZNF367. J BUON. 23:1413–1419. 2018.PubMed/NCBI
|
|
31
|
Jiang W, He Y, Shi Y, Guo Z, Yang S, Wei
K, Pan C, Xia Y and Chen Y: MicroRNA-1204 promotes cell
proliferation by regulating PITX1 in non-small cell lung cancer.
Cell Biol Int. 43:253–264. 2019.
|
|
32
|
Liu Q, Chen J, Wang B, Zheng Y, Wan Y,
Wang Y, Zhou L, Liu S, Li G and Yan Y: miR-145 modulates
epithelial-mesenchymal transition and invasion by targeting ZEB2 in
non-small cell lung cancer cell lines. J Cell Biochem. 2018.
|
|
33
|
Gu B, Wang J, Song Y, Wang Q and Wu Q:
microRNA-383 regulates cell viability and apoptosis by mediating
Wnt/β-catenin signaling pathway in non-small cell lung cancer. J
Cell Biochem. 2018.
|
|
34
|
Wang Y, Yu L and Wang T: MicroRNA-374b
inhibits the tumor growth and promotes apoptosis in non-small cell
lung cancer tissue through the p38/ERK signaling pathway by
targeting JAM-2. J Thorac Dis. 10:5489–5498. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiang F, Yu Q, Chu Y, Zhu X, Lu W, Liu Q
and Wang Q: MicroRNA-98-5p inhibits proliferation and metastasis in
non-small cell lung cancer by targeting TGFBR1. Int J Oncol.
54:128–138. 2019.
|
|
36
|
Xie Q, Yu Z, Lu Y, Fan J, Ni Y and Ma L:
microRNA-148a-3p inhibited the proliferation and
epithelial-mesenchymal transition progression of non-small-cell
lung cancer via modulating Ras/MAPK/Erk signaling. J Cell Physiol.
234:12786–12799. 2019. View Article : Google Scholar
|
|
37
|
Zheng HE, Wang G, Song J, Liu Y, Li YM and
Du WP: MicroRNA-495 inhibits the progression of non-small-cell lung
cancer by targeting TCF4 and inactivating Wnt/β-catenin pathway.
Eur Rev Med Pharmacol Sci. 22:7750–7759. 2018.PubMed/NCBI
|
|
38
|
Ma W, Feng W, Tan J, Xu A, Hu Y, Ning L,
Kang Y, Wang L and Zhao Z: miR-497 may enhance the sensitivity of
non-small cell lung cancer cells to gefitinib through targeting the
insulin-like growth factor-1 receptor. J Thorac Dis. 10:5889–5897.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Z, Qiao Q, Chen M, Li X, Wang Z, Liu
C and Xie Z: miR-625 down-regulation promotes proliferation and
invasion in esophageal cancer by targeting Sox2. FEBS Lett.
588:915–921. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou X, Zhang CZ, Lu SX, Chen GG, Li LZ,
Liu LL, Yi C, Fu J, Hu W, Wen JM and Yun JP: miR-625 suppresses
tumour migration and invasion by targeting IGF2BP1 in
hepatocellular carcinoma. Oncogene. 35:50782016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fang W, Fan Y, Fa Z, Xu J, Yu H, Li P and
Gu J: microRNA-625 inhibits tumorigenicity by suppressing
proliferation, migration and invasion in malignant melanoma.
Oncotarget. 8:13253–13263. 2017.PubMed/NCBI
|
|
42
|
Zhang J, Zhang J, Zhang J, Qiu W, Xu S, Yu
Q, Liu C, Wang Y, Lu A, Zhang J and Lu X: MicroRNA-625 inhibits the
proliferation and increases the chemosensitivity of glioma by
directly targeting AKT2. Am J Cancer Res. 7:1835–1849.
2017.PubMed/NCBI
|
|
43
|
Hong CS, Jeong O, Piao Z, Guo C, Jung MR,
Choi C and Park YK: HOXB5 induces invasion and migration through
direct transcriptional up-regulation of β-catenin in human gastric
carcinoma. Biochem J. 472:393–403. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xu H, Zhao H and Yu J: HOXB5 promotes
retinoblastoma cell migration and invasion via ERK1/2
pathway-mediated MMPs production. Am J Transl Res. 10:1703–1712.
2018.PubMed/NCBI
|
|
45
|
Lee JY, Hur H, Yun HJ, Kim Y, Yang S, Kim
SI and Kim MH: HOXB5 promotes the proliferation and invasion of
breast cancer cells. Int J Biol Sci. 11:701–711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tucci R, Campos MS, Matizonkas-Antonio LF,
Durazzo M, Pinto Junior Ddos S and Nunes FD: HOXB5 expression in
oral squamous cell carcinoma. J Appl Oral Sci. 19:125–129. 2011.
View Article : Google Scholar : PubMed/NCBI
|
